CHRISTOPHER LEMONS: Open Payments
NPI 1023657236 · ANDOVER, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,862 in 106 payments from 24 companies in 2025. Trend: 2023 $415 · 2024 $1,619 · 2025 $1,862
Food & beverage: $1,862
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $306 |
| Lilly USA, LLC | 10 | $175 |
| Amgen Inc. | 12 | $174 |
| PFIZER INC. | 14 | $163 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $107 |
| Vanda Pharmaceuticals Inc. | 3 | $90 |
| Ardelyx, Inc. | 5 | $86 |
| Novo Nordisk Inc | 5 | $86 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $84 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $71 |
Products named: FARXIGA, MOUNJARO, Kerendia, AIRSUPRA, OTEZLA, REXULTI, IBSRELA, XIFAXAN.
Industry payments across KS — which companies pay providers there.
